Skip to content
Eiko Lifesciences logo

Eiko Lifesciences

540204 BSE
₹50.81

Close ·

P/E
14.56
View as Markdown
MCP
Close 4 Nov 2026 ₹50.81 −6.68 −11.6% 1Y
Start ₹57.49

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
11.10%
Debt to Equity
0.07
EPS (TTM)
₹3.49
Book Value
₹45.32
Market Cap
—
P/E (TTM)
14.56
P/B
1.12
ROE
8.47%
Dividend Yield
0.00%
EBITDA
₹8.40 Cr
52W High
₹64.25
52W Low
₹43.00

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

58 Good

Data confidence 98/100

Category scores

Quality
46
Average
Returns, margins, earnings quality 22% weight
Valuation
58
Good
Cheap vs sector & own history 24% weight
Growth
92
Strong
Sales & profit trajectory 9% weight
Financial Health
78
Strong
Solvency, leverage, coverage 9% weight
Momentum
64
Good
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 0.99 times its book value
  • Company is expected to give good quarter

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding is low: 39.9%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish0712
OscillatorsBullish072
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
54.70
Neutral
MACD (12,26,9)
0.68
Bullish
SMA (50)
48.12
Bullish
SMA (200)
50.14
Bullish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5YIrregular period
3YIrregular period
1Y+39.59%
TTM+56.10%

Net profit

Net profit growth by window
5YIrregular period
3YIrregular period
1Y+129.31%
TTM+87.25%

Operating cash flow

Operating cash flow growth by window
5YIrregular period
3YIrregular period
1Y−19.06%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5YIrregular period
3YIrregular period
1Y+6.58 pp
TTM+3.01 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2018₹2.36 Cr
Mar 2019₹4.27 Cr
Mar 2020₹10.40 Cr
Mar 2025₹37.66 Cr
Mar 2026₹52.57 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2018₹0.20 Cr
Mar 2019−₹0.78 Cr
Mar 2020−₹3.62 Cr
Mar 2025₹2.32 Cr
Mar 2026₹5.32 Cr

Quarterly Results

₹ Cr
540204 quarterly results, ₹ crore
Particulars Dec 2019Mar 2020Jun 2020Sep 2020Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
3.2
0.62
0.56
0.84
10.75
8.16
7.49
11.27
10.71
11.67
11.98
18.34
16.75
Expenses
4.55
1.53
0.42
0.89
10.35
7.73
6.86
9.95
9.2
9.9
10.1
16.08
14.82
Operating Profit
−1.35
−0.91
0.14
−0.05
0.4
0.43
0.63
1.32
1.51
1.77
1.88
2.26
1.93
OPM %
−42.19%
−146.77%
25%
−5.95%
3.72%
5.27%
8.41%
11.71%
14.1%
15.17%
15.69%
12.32%
11.52%
Other Income
0.01
−0.04
0.05
0.01
0.26
0.13
0.12
0.64
0.27
0.3
0.35
0.13
0.45
Interest
0.08
0.03
0.01
0.1
0.03
0.04
0.03
0.07
0.05
0.1
0.07
0.12
0.13
Depreciation
0.05
0.05
0.04
0.04
0.17
0.16
0.16
0.25
0.25
0.26
0.26
0.25
0.25
PBT
−1.47
−1.03
0.14
−0.18
0.46
0.36
0.56
1.64
1.48
1.71
1.9
2.02
2
Tax %
−25.85%
−28.16%
28.57%
−22.22%
26.09%
27.78%
25%
23.78%
25%
24.56%
24.74%
25.74%
24.5%
Net Profit
−1.08
−0.74
0.1
−0.13
0.37
0.28
0.42
1.25
1.11
1.29
1.43
1.5
1.51
EPS (₹)
−0.92
−0.64
0.09
−0.08
0.3
0.22
0.33
0.84
0.66
0.79
0.88
0.91
0.91

Profit & Loss

₹ Cr
540204 profit and loss, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2025Mar 2026TTM
Sales
2.36
4.27
10.4
37.66
52.57
58.74
Expenses
1.98
4.95
14.91
34.89
45.24
50.9
Operating Profit
0.38
−0.68
−4.51
2.77
7.33
7.84
OPM %
16.1%
−15.93%
−43.37%
7.36%
13.94%
13.35%
Other Income
0.04
0.04
0.01
1.2
1.16
1.23
Interest
0.09
0.19
0.24
0.17
0.36
0.42
Depreciation
0.08
0.17
0.19
0.74
1.02
1.02
PBT
0.25
−1
−4.93
3.06
7.11
7.63
Tax %
20%
−21%
−26.77%
24.51%
25.18%
—
Net Profit
0.2
−0.78
−3.62
2.32
5.32
5.73
EPS (₹)
0.31
−0.69
−2.98
1.86
3.71
3.49
Div. Payout %
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
540204 balance sheet, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2025Mar 2026
Equity Capital
3.82
3.82
3.82
13.76
14.35
Reserves
1.74
1.1
−0.87
43.03
54.44
Borrowings
1.74
1.37
1.61
2.76
4.73
Other Liabilities
3.66
3.01
7.49
6.56
15.85
Total Liabilities
10.96
9.3
12.05
66.11
89.37
Fixed Assets
1.68
1.71
1.75
23.12
22.1
CWIP
0
0
0
0
0
Investments
3.17
1.72
0.1
7.15
15.29
Other Assets
6.11
5.87
10.2
35.84
51.98
Total Assets
10.96
9.3
12.05
66.11
89.37

Cash Flow

₹ Cr
540204 cash flow, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2025Mar 2026
Operating
0
0.16
−0.33
2.78
2.25
Investing
0
−0.3
−0.71
−11.3
−8.63
Financing
0
−0.55
0.95
6.96
8.21
Net Cash Flow
0
−0.69
−0.09
−1.57
1.83
Free Cash Flow
0
−0.04
−0.56
−7.51
2.25
CFO/OP
0
−26
7
112
50

Ratios

540204 financial ratios, annual
Particulars Mar 2018Mar 2019Mar 2020Mar 2025Mar 2026
Debtor Days
226
73.51
41.41
105
140
Inventory Days
820
288
154
64.48
35.09
Days Payable
606
174
185
36.99
111
Cash Conversion Cycle
440
187
10.72
132
64.46
Working Capital Days
80.42
−1.71
−152
144
128
ROCE %
—
−11.83%
−105.39%
—
11.12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Eiko Lifesciences insights

64 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 41.31%
  • Promoters 39.96%
  • Others 18.72%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

  • Concall · May 2023
    PPT
  • Q1 FY22 concall · Jul 2021
    PPT
  • Concall · Apr 2021
    PPT
  • Q3 FY21 concall · Feb 2021
    PPT
  • Concall · Nov 2020
    PPT

Frequently Asked Questions about Eiko Lifesciences

What does Eiko Lifesciences Ltd do?
Incorporated in 2021, Eiko LifeSciences Ltd manufacturing & sells Specialty Chemical and Fine Chemicals
Where is Eiko Lifesciences Ltd (EIKO) listed?
Eiko Lifesciences Ltd trades under code 540204 on the BSE.
Which sector does Eiko Lifesciences Ltd belong to?
Eiko Lifesciences Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the PE ratio of Eiko Lifesciences Ltd?
Eiko Lifesciences Ltd trades at a PE ratio of 14.56 as of 4 Nov 2026, on earnings per share of ₹3.49, against a book value of ₹45.32 per share.
What is the 52-week high and low of Eiko Lifesciences Ltd?
Over the last 52 weeks Eiko Lifesciences Ltd has traded between ₹43 and ₹64.25 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Eiko Lifesciences Ltd?
Eiko Lifesciences Ltd reported a return on equity of 8.47%. Its debt-to-equity ratio is 0.07.

Company Information

Incorporated in 2021, Eiko LifeSciences Ltd manufacturing & sells Specialty Chemical and Fine Chemicals

Website eikolifesciences.com
Listed 13 Dec 2016
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540204.md for Eiko Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month